Study study type PathologyT1T0Patientssample sizesROB Results

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

versus Standard of Care (SoC)
talazoparib
EMBRACA, 2018
  NCT01945775
RCTmBC-Triple negative (TNBC) - 2nd Line (L2)talazoparibchemotherapyPatients with HER2-negative locally advanced or metastatic breast cancer and a deleterious or suspected deleterious gBRCA1/2 mutation. Patients had received 3 or less previous cytotoxic regimens for advanced disease and previous treatment with a taxane, an anthracycline, or both (unless contraindicated).287 / 144NA
conclusif
  • inconclusive 15 % decrease in deaths (OS) (PE)
  • demonstrated 46 % decrease in progression or deaths (PFS) (PE)
  • demonstrated 4.0-fold increase in objective responses (ORR) (PE)

mBC - TNBC - L2 - all population breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - all population

versus Standard of Care (SoC)
olaparib
OlympiAD, 2017
  NCT02000622
RCTmBC - TNBC - L2 - all populationolaparibstandard chemotherapyPatients with HER-2 negative metastatic breast cancer that was HR positive or triple negative. Patients had a confirmed deleterious or suspected deleterious germline BRCA mutation and had receive no more than 2 previous chemotherapy regimens for metastatic disease.205 / 97NA
conclusif
  • inconclusive 10 % decrease in deaths (OS) (PE)
  • demonstrated 42 % decrease in progression or deaths (PFS) (PE)